skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current and developing therapeutic agents in the treatment of Chagas disease

Review

(1889) Views  (663) Full article downloads

Authors: Werner Apt

Published Date September 2010 Volume 2010:4 Pages 243 - 253
DOI: http://dx.doi.org/10.2147/DDDT.S8338

Werner Apt
University of Chile, Faculty of Medicine, Santiago, Chile

Abstract: Chagas disease must be treated in all its stages: acute, indeterminate, chronic, and initial and middle determinant chronic, due to the fact that DNA of the parasite can be demonstrated by PCR in chronic cases, where optical microscopy does not detect parasites. Nifurtimox (NF) and benznidazole (BNZ) are the drugs accepted to treat humans based upon ethical considerations and efficiency. However, both the drugs produce secondary effects in 30% of the cases, and the treatment must be given for at least 30–60 days. Other useful drugs are itraconazole and posaconazole. The latter may be the drug to treat Chagas disease in the future when all the investigations related to it are finished. At present, there is no criterion of cure for chronic cases since in the majority, the serology remains positive, although it may decrease. In acute cases, 70% cure with NF and 75% with BNZ is achieved. In congenital cases, 100% cure is obtained if the treatment is performed during the first year of life. In chronic acquired cases, 20% cure and 50% improvement of the electrocardiographic changes are obtained with itraconazole.

Keywords: Chagas disease, treatment, nifurtimox, benznidazole, allopurinol, itraconazole, posaconazole






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
ABO and rhesus blood group distribution in Kurds
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Thermosensitive Pluronic® hydrogel: prolonged injectable formulation for drug abuse
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Perception of risk and benefit in patient-centered communication and care
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University